Experts worry about the growing incidence of inflammatory bowel disease in Kuwait

"At Takeda, we aim to improve the lives of patients with gastrointestinal illness through the provision of innovative medicines that target the underlying causes of the disease." Our continued dedication to advanced research in the area of ​​IBD is based on our deep understanding of the challenges that dictate the unique needs of people with IBD and the physicians who treat them.Beyond medicine, we take a closer look at the patient's experience and work to provide tools for better management of the disease, "said Maged Kamel, Medical Executive Director & Regulatory & AQ of Takeda Middle East, Middle East and Africa.

When an IBD is suspected based on the symptoms and medical history of someone, a series of tests is used to confirm the diagnosis. These tests may include a blood test, a stool sample, an endoscopic procedure, and an imaging procedure. Treatment can take the form of medications, surgical procedures, nutritional supplements or a combination of these options. The goals of treatment are to induce remission, prevent disease outbreaks and improve quality of life.^[xiv],[xv]

Various stakeholders, including governments, communities, hospitals, and the pharmaceutical industry can play a collaborative role in raising awareness of ITNs in Kuwait and the region, and become active advocates for the lives of people with colitis. ulcerative and Crohn's disease. ).

About Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global pharmaceutical company, focused on research and development, committed to improving health and providing a better future for patients by translating science into life-changing medicines. Takeda focuses its R & D efforts on the therapeutic areas of oncology, gastroenterology and neuroscience plus vaccines. Takeda conducts R & D activities internally and with partners to stay at the forefront of innovation. Innovative products, including oncology and gastroenterology, as well as Takeda's presence in emerging markets are currently fueling Takeda's growth. About 30,000 Takeda employees are committed to improving the quality of life of patients, working with Takeda's healthcare partners in more than 70 countries. For more information, visit https://www.takeda.com

For more information please contact

Takeda Pharmaceuticals FZCO – NEMEA

Lamia Hotait

Associate Director of Communications (Middle East, Middle East and Africa)

T: +9714 601 4742

E: [email protected]

Memac Ogilvy Public Relations

Mimi Alexander

[email protected]

+965 22258719

[i]Centers for Disease Control. Inflammatory bowel disease. http://www.cdc.gov/ibd/. Updated July 15, 2011.Accessed on February 11, 2013.

[ii]The Canadian Crohn's and Colitis Foundation. The Burden of Inflammatory Bowel Disease (IBD) in Canada. http://www.isupportibd.ca/pdf/ccfc-ibd-impact-report-2012.pdf. Published November 2012.Accessed on February 11, 2013.

[iii] Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence and environmental influences. Gastroenterology.2004; 126 (6): 1504-1517. http://download.journals.elsevierhealth.com/pdfs/journals/0016-5085/PIIS0016508504004627.pdf. Accessed March 1, 2013.

[iv]Wilson J, Hair C, Knight R et al. High incidence of inflammatory bowel disease in Australia: a prospective Australian population-based incidence study. Inflamm Bowel Dis. 2010; 16 (9): 1550-1556.

[v]Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J. Gastroenterol. 2009; 44: 659-665.

[vi]Sood A, Midha V, Sood N, AS Bhatia, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Intestine. 2003; 52: 1587-1590.

[vii] https://www.hindawi.com/journals/cjgh/2017/6496727/

[viii] Foundation of Crohn's disease and Colitis of America. The facts about inflammatory bowel disease. http://www.ccfa.org/assets/pdfs/updatedibdfactbook.pdf. Published in November 2014. Accessed 23 April 2015

[ix]Knigge KL. Inflammatory disease of the intestine.Clin Cornerstone. 2002; 4 (4): 49-60.

[x]Foundation of Crohn's disease and Colitis of America. The facts about inflammatory diseases of the intestines. http://www.ccfa.org/assets/pdfs/ibdfactbook.pdf. Published in June 2011.Accessed on January 4, 2013.

[xi]National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Information on Digestive Diseases. Crohn's disease. http://digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.aspx. Published December 2011. Accessed March 1, 2013.

[xii]National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Information on Digestive Diseases. Ulcerative colitis. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.aspx. Published October 2011. Accessed March 1, 2013.

[xiii] National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Information on Digestive Diseases. Ulcerative colitis

[xiv]National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Information on Digestive Diseases. Ulcerative colitis.

[xv]Foundation of Crohn's disease and Colitis of America. Treatment options in ITNs. http://www.ccfa.org/resources/treatment-options-in-ibd.html. Accessed June 9, 2015.

[xv]^IYulan Ye, Zhi Pang, etal, Epidemiology and Risk Factors of Inflammatory Bowel Disease, Int J Clin Exp Med. 2015; 8 (12): 22529-22542.

© Press Release 2018